Completely normal
And to help you with this, we proudly introduce this online course: Implementing Semaglutide and Tirzepatide into your Aesthetic Practice Your golden ticket to unlocking the full potential of your practice
The phase 3 SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) clinical trial program evaluated the efficacy and safety of semaglutide in subjects with T2D in a range of patient populations across the continuum of diabetes care [7,8,9,10,11,12,13,14]
The criteria we use to decide if our patient is an appropriate candidate for our program are BMI (Body mass index of 25 kg/m2 or higher or the presence of one or more weight-related conditions like high blood pressure, type 2 diabetes, high cholesterol, increased risk of cardiovascular disease, fatty liver or metabolic syndrome
While it may not lower cholesterol as dramatically as statins, its multi-faceted approach can benefit patients, especially those with type 2 diabetes and obesity